| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7125899 | R-PHARM US LLC | Epothilone derivatives |
May, 2018
(5 years ago) | |
| USRE41911 | R-PHARM US LLC | Epothilone derivatives |
Sep, 2020
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7125899 (Pediatric) | R-PHARM US LLC | Epothilone derivatives |
Nov, 2018
(5 years ago) | |
|
USRE41911 (Pediatric) | R-PHARM US LLC | Epothilone derivatives |
Mar, 2021
(3 years ago) | |
| US6670384 | R-PHARM US LLC | Methods of administering epothilone analogs for the treatment of cancer |
Jan, 2022
(2 years ago) | |
| US7022330 | R-PHARM US LLC | Parenteral formulation for epothilone analogs |
Jan, 2022
(2 years ago) | |
| USRE41393 | R-PHARM US LLC | Treatment of refractory tumors using epothilone derivatives |
Feb, 2022
(2 years ago) | |
|
US6670384 (Pediatric) | R-PHARM US LLC | Methods of administering epothilone analogs for the treatment of cancer |
Jul, 2022
(1 year, 8 months ago) | |
|
US7022330 (Pediatric) | R-PHARM US LLC | Parenteral formulation for epothilone analogs |
Jul, 2022
(1 year, 8 months ago) | |
|
USRE41393 (Pediatric) | R-PHARM US LLC | Treatment of refractory tumors using epothilone derivatives |
Aug, 2022
(1 year, 8 months ago) | |
| US7312237 | R-PHARM US LLC | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
Aug, 2024
(4 months from now) | |
|
US7312237 (Pediatric) | R-PHARM US LLC | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
Feb, 2025
(10 months from now) | |
Ixempra Kit is owned by R-Pharm Us Llc.
Ixempra Kit contains Ixabepilone.
Ixempra Kit has a total of 12 drug patents out of which 10 drug patents have expired.
Expired drug patents of Ixempra Kit are:
- US7125899*PED
- USRE41911*PED
- US6670384
- US7022330
- USRE41393
- US6670384*PED
- US7022330*PED
- USRE41393*PED
- US7125899
- USRE41911
Ixempra Kit was authorised for market use on 16 October, 2007.
Ixempra Kit is available in injectable;intravenous dosage forms.
Ixempra Kit can be used as a method of treating cancer in a patient comprising administering ixabepilone or pharmaceutical compositions comprising ixabepilone, use of ixabepilone in combination with capecitabine in treatment of metastasis breast cancer, method of treating breast cancer by administering ixabepilone; a method of treating a cancer responsible to microtubule stabilization by administering ixabepilone, method of treating cancer, iv admin, lyophilized ixabepilone diluted, every week or 3 weeks; lyophilized ixabepilone with solvent(dehydrated ethanol) diluted to concentration of 0.1mg/ml to 0.9mg/ml, method of treating patient comprising mixing first and second vials of product comprising lyophilized ixabepilone to provide an epothilone analog solution, diluting solution with a suitable diluent to prepare intravenous formulation for pt.
Drug patent challenges can be filed against Ixempra Kit from 18 April, 2014.
The generics of Ixempra Kit are possible to be released after 21 February, 2025.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 16, 2012 |
| M(M-61) | Oct 18, 2014 |
| Pediatric Exclusivity(PED) | Apr 18, 2015 |
Drugs and Companies using IXABEPILONE ingredient
NCE-1 date: 18 April, 2014
Market Authorisation Date: 16 October, 2007
Treatment: Method of treating cancer, iv admin, lyophilized ixabepilone diluted, every week or 3 weeks; Lyophilized ixabepilone with solvent(dehydrated ethanol) diluted to concentration of 0.1mg/ml to 0.9mg/ml...
Dosage: INJECTABLE;INTRAVENOUS
IXEMPRA KIT family patents
